A strong financial performance 

Results for the year ended 30 June 2016:

  • Adjusted gross profit1 up 90%, driven by Acquisitions and organic growth
  • Adjusted EPS1 up 25% to 35.0p (2015: 28.0p)
  • Reported EPS of 11.9p (2015: 6.5p) after one off acquisition costs and post acquisition restructuring costs
  • £49.4m cash generated from operations, up 213% 
  • Net debt decreased £8.1m to £68.1m after £28.5m spent on acquisitions
  • Full year dividend increased 18% to 4.0p (2015: 3.4p) 
  • Strongest performances by Specialty Pharmaceuticals (‘SP’), driven by revitalisation of newer products2, and Clinical Trial Services (‘CTS’)
  • Integration of Idis and Link Healthcare (‘Link’) acquisitions substantially complete 
  • Acquisition of Totect and Foscavir bag line extension enhances SP portfolio

1 The adjusted results exclude share based payment costs, amortisation, non-underlying costs and include the 50% share of the unaudited results from the Joint Venture (‘JV’) in South Africa
2 Newer products
refers to Ethyol, Cardioxane, and Savene